Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging-Reference-Cited by-同舟云学术

Prolonged impacts of sodium glucose cotransporter-2 inhibitors on metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: a retrospective analysis through magnetic resonance imaging

Published:2024 Issue:8 Volume:71 Page:767-775
ISSN:0918-8959
Container-title:Endocrine Journal
language:en
Short-container-title:Endocr J

Author:

Suzuki Agena¹,Hayashi Akinori¹^ORCID,Oda Satoshi¹,Fujishima Rei¹,Shimizu Naoya¹,Matoba Kenta¹,Taguchi Tomomi¹,Toki Takuya¹,Miyatsuka Takeshi¹

Affiliation:

1. Department of Endocrinology, Diabetes and Metabolism, Kitasato University School of Medicine, Kanagawa 252-0374, Japan

Publisher

Japan Endocrine Society

Link

https://www.jstage.jst.go.jp/article/endocrj/71/8/71_EJ24-0005/_pdf

Reference43 articles.

1. 1 Alisi A, Manco M, Pezzullo M, Nobili V (2011) Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis. Hepatology 53: 372–373.

2. 2 Targher G, Byrne CD (2013) Clinical review: nonalcoholic fatty liver disease: a novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 98: 483–495.

3. 3 Wong VW, Wong GL, Yeung DK, Lau TK, Chan CK, et al. (2015) Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 62: 182–189.

4. 4 Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, et al. (2023) A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology 78: 1966–1986.

5. 5 Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, et al. (2023) The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 77: 1335–1347.